The discovery of antiangiogenic molecules: A historical review

Current Pharmaceutical Design

Volumn 15, Issue 4, 2009, Pages 345-352

  Ribatti, Domenico ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Angiogenesis; Antiangiogenesis; History of medicine; Tumor growth

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BAT 439006; BEVACIZUMAB; CAPLOSTATIN; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4; CORTISONE; CYCLOPHOSPHAMIDE; DENIBULIN; ENDOSTATIN; FLAVONOID; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMTUZUMAB OZOGAMICIN; HEPARIN; IBRITUMOMAB TIUXETAN; N ACETYLCOLCHINOL PHOSPHATE; PROTAMINE; RECOMBINANT THROMBOCYTE FACTOR 4; RITUXIMAB; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; SORAFENIB; SUNITINIB; THALIDOMIDE; THROMBOSPONDIN 1; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR TARGETING AGENT; VATALANIB;

ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; B CELL LYMPHOMA; BLEEDING; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER INHIBITION; CELL FUNCTION; CELL SURVIVAL; CHORIOALLANTOIS; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTINUOUS INFUSION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG INTERMITTENT THERAPY; DRUG RESEARCH; DRUG TARGETING; EDEMA; ENDOTHELIUM CELL; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL STROMAL TUMOR; HAIR LOSS; HAND FOOT SYNDROME; HEMANGIOENDOTHELIOMA; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INHIBITION KINETICS; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKOPENIA; LYMPHOCYTOPENIA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; SKIN DISEASE; TERATOGENICITY; THROMBOEMBOLISM; TREATMENT DURATION; TUMOR VASCULARIZATION; WOUND HEALING IMPAIRMENT; CLASSIFICATION; DRUG DEVELOPMENT; NEOVASCULARIZATION (PATHOLOGY);

ANGIOGENESIS INHIBITORS; DRUG DISCOVERY; HUMANS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 64249120430     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787315855     Document Type: Review

References (62)

1. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-6.
2. White CW, Sandheimer HM, Crouch EC, Wilson H, Fan LL. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med 1989; 320: 1197-200.
3. Folkman J. Successful treatment of an angiogenesis disease. N Engl J Med 1989; 320: 1211-2.
4. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for lifethreatening hemangiomas of infancy. N Engl J Med 1992; 326: 1456-63.
5. Kaban LB, Mulliken JB, Ezekowiyz RA, Ebb D, Smith PS, Folkman J. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alpha-2a. Pediatrics 1999; 103: 1145-9.
6. Kaban LB, Troulis MJ, Ebb D, August M, Hornicek FJ, Dodson TB. Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws. J Oral Maxillofac Surg 2002; 60: 1103-11.
7. Ginns LC, Roberts DH, Mark EJ, Brush JL, Marler JJ. Pulmonary capillary hemangiomatosis with atypical endotheliomatosis: Successul antiangiogenic therapy with doxycycline. Chest 2003; 124: 2017-22.
8. Langer R, Cohn M, Vacanti J, Haudenschild C, Folkman J. Control of tumor growth in animals by infusion of an angiogenesis inhibitor. Proc Natl Acad Sci USA 1980; 77: 4331-5.
9. Moses MA, Sudhalter J, Langer R. Identification of an inhibitor of neovascularization from cartilage. Science 1990; 248: 1408-10.
10. Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumor therapy. Br J Cancer 1982; 45: 136-9.
11. Denekamp J, Hill SA, Hobson B. Vascular occlusion and tumour cell death. Eur J Cancer Clin Oncol 1983; 19: 271-5.
12. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005; 5: 423-35.
13. Folkman J, Langer R, Linhardt R, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983; 221: 719-25.
14. Linhardt R, Grant A, Cooney C, Langer R. Differential anticoagulant activity of heparin fragments prepared using microbial heparinase. J Biol Chem 1982; 257: 7310-3.
15. Taylor S, Folkman J. Protamine is an inhibitor of angiogenesis. Nature 1982; 297: 307-12.
16. Crum R, Szabo S, Folkman J. A new class of streroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985; 230: 1375-8.
17. Ingber DE, Madri JA, Folkman J. A possible mechanism for inhibition of angiogenesis by angiostatic steroids: Induction of capillary basement membrane dissolution. Endocrinology 1986; 119: 1768-75.
18. D'Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E. 2Methoxyestradiol, an endogenous mammalian metabolite inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA 1994; 91: 3964-8.
19. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 468: 555-7.
20. Milkowski DM, Weiss RA. TNP 470. In: Teicher BA Ed, Antiangiogenic Agents in Cancer Therapy. Totowa, NJ, Humana 1999; 385-98.
21. Satchi-Fainaro R, Mamluk R, Wang L, Short SM, Nagy JA, Feng D, et al. Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell 2005; 7: 251-61.
22. Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, et al. Inhibition of angiogenesis by recombinant human platelet factor- 4 and related peptides. Science 1990; 247: 77-9.
23. Sharpe RJ, Byers HR, Scott CF, Bauer SI, Maione TE. Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst 1990; 82: 848-53.
24. Kolber DL, Knisely TL, Maione TE. Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. J Natl Cancer Inst 1995; 87: 304-9.
25. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, et al. A tumor-suppressor dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990; 87: 6624-8.
26. Taraboletti G, Roberts D, Liotta LA, Giavazzi R. Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: A potential angiogenesis regulatory factor. J Cell Biol 1990; 111: 765-72.
27. Iruela-Arispe ML, Bornstein P, Sage H. Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc Natl Acad Sci USA 1991; 88: 5026-30.
28. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002; 6: 1-12.
29. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
30. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689-92.
31. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
32. Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E, et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001; 61: 7669-774.
33. Sund M, Hanano Y, Sugimoto H, Sudhakar A, Soubasakos M, Yerremalla U, et al. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci USA 2005; 102: 2934-9.
34. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-7.
35. Folkman J, Jalluri R. Tumor angiogenesis. In: Kufe DW, Pollock RE, Weichselbaum RR, Eds. Cancer Medicine, Hamilton, Ontario, BC Decker 2003; 161-94.
36. Abdollahi A, Hahnfeldt P, Maercker C, Grone HJ, Debus J, Ansorge W, et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004; 13: 649-63.
37. Mellin GW, Katzenstein M. The saga of thalidomide. N Engl J Med 1962; 267: 1184-93.
38. D'Amato RJ, Loughman MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-5.
39. Ribatti D, Vacca A. Therapeutic renaissance of thalidomide in the treatment of haematological malignancies. Leukemia 2005; 19: 1523-31.
40. Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW, et al. Novel thalidomide analogous display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002; 87: 1166-72.
41. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878-86.
42. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000; 105: 1045-7.
43. Gasparini G, longo R, Fanelli M, Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: Results, challenges, and open questions. J Clin Oncol 2005; 23: 1295-311.
44. Garcia Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300: 964-7.
45. Bergers G, Song S, Mayer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111: 1287-95.
46. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels and appearance of basement membrane ghosts. Am J Pathol 2004; 165: 35-52.
47. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3: 24-40.
48. Smith JK, Mamoon NM, Duher RJ. Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. Oncol Res 2004; 14: 175-225.
49. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, et al. PTK 787/ZK222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178-89.
50. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99: 11393-8.
51. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005; 65: 671-80.
52. Hurwitz H, Fehrenbacker K, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
53. Keedy VL, Sandler AB. Inhibition of angiogenesis in the treatment of non-small cell lung cancer. Cancer Sci 2007; 98: 1825-30.
54. Salter JT, Miller KD. Antiangiogenic agents in breast cancer. Cancer Invest 2007; 25: 518-26.
55. Gragoudas ES, Adams AP, Cunningham RT Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-16.
56. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59: 5209-18
57. Kuenen BC, Rpsen L, Smith EF, Parson MR, Levi M, Ruijter R, et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabile and SU5416 in patients with solid tumors. J Clin Oncol 2002; 20: 1657-67
58. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30: 117-24.
59. Novak K. Angiogenesis inhibitors revised and revived at AACR. Nat Med 2002; 8: 427.
60. Bernard MP, Bancos S, Sime PJ, Phipps RP. Targeting cyclooxygenase-2 in hematological malignancies: Rationale and promise. Curr Pharm Des 2008; 14(21): 2051-60.
61. Mischiati C, Melloni E, Corallini F, Milani D, Bergamini C, Vaccarezza M. Potential role of PKC inhibitors in the treatment of hematological malignancies. Curr Pharm Des 2008; 14(21): 2075-84.
62. Spankuch B, Strebhardt K. Combinatorial application of nucleic acid-based agents targeting protein kinases for cancer treatment. Curr Pharm Des 2008; 14(11): 1098-112.